Drug Type Bispecific antibody |
Synonyms- |
Mechanism ICOSLG modulators(ICOS ligand modulators), KIR inhibitors(Killer cell immunoglobulin like receptors inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Mozart Therapeutics, Inc.Startup |
Active Organization Mozart Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Preclinical | US | Mozart Therapeutics, Inc.Startup | 16 May 2024 |